Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Michaut, Magali ^a   Chin, Suet Feung ^b   Majewski, Ian ^a   Severson, Tesa M ^a   Bismeijer, Tycho ^a   De Koning, Leanne ^c   Peeters, Justine K ^d   Schouten, Philip C ^a   Rueda, Oscar M ^b   Bosma, Astrid J ^a   Tarrant, Finbarr ^e,f   Fan, Yue ^e   He, Beilei ^c   Xue, Zheng ^a   Mittempergher, Lorenza ^a   Kluin, Roelof J C ^a   Heijmans, Jeroen ^d   Snel, Mireille ^d   Pereira, Bernard ^b   Schlicker, Andreas ^a   Provenzano, Elena ^g   Ali, Hamid Raza ^b   Gaber, Alexander ^h   O'Hurley, Gillian ^f   Lehn, Sophie ^h   Muris, Jettie J F ^a   Wesseling, Jelle ^a   Kay, Elaine ⁱ   Sammut, Stephen John ^b   Bardwell, Helen A ^b   Barbet, Aurélie S ^c   Bard, Floriane ^c   Lecerf, Caroline ^c   O'Connor, Darran P ^e   Vis, Daniël J ^a   Benes, Cyril H ^j   McDermott, Ultan ^k   Garnett, Mathew J ^k   Simon, Iris M ^d   Jirström, Karin ^h   Dubois, Thierry ^c   Linn, Sabine C ^a,l   Gallagher, William M ^e,f   Wessels, Lodewyk F A ^a,m   Caldas, Carlos ^b,g,n   Bernards, Rene ^a,d   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c INSTITUT CURIE   (France)

^d Agendia NV   (Netherlands)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

^f ONCOMARK LIMITED   (Ireland)

^g CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h LUND UNIVERSITY   (Sweden)

ⁱ BEAUMONT HOSPITAL   (Ireland)

^j HARVARD MEDICAL SCHOOL   (United States)

^k WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^l UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^m DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

ⁿ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; ELF4 PROTEIN, HUMAN; PROTEOME; TRANSCRIPTION FACTOR; TRANSCRIPTOME; TUMOR MARKER;

BREAST NEOPLASMS; CARCINOMA, LOBULAR; CLUSTER ANALYSIS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MORTALITY; MUTATION RATE; PROCEDURES; PROGNOSIS; PROTEOMICS; REPRODUCIBILITY; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, LOBULAR; CLUSTER ANALYSIS; DNA-BINDING PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION RATE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION FACTORS; TRANSCRIPTOME;

EID: 84953278990     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18517     Document Type: Article

References (45)

1. Guiu, S. et al. Invasive lobular breast cancer and its variants: How special are they for systemic therapy decisions? Critical reviews in oncology/hematology, doi: 10.1016/j.critrevonc.2014.07.003 (2014).
2. Pestalozzi, B. C. et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: Combined results of 15 International Breast Cancer Study Group clinical trials. Journal of Clinical Oncology 26, 3006-3014, doi: 10.1200/JCO.2007.14.9336 (2008).
3. Iorfida, M. et al. Invasive lobular breast cancer: Subtypes and outcome. Breast cancer research and treatment 133, 713-723, doi: 10.1007/s10549-012-2002-z (2012).
4. Arpino, G., Bardou, V. J., Clark, G. M. & Elledge, R. M. Infiltrating lobular carcinoma of the breast: Tumor characteristics and clinical outcome. Breast cancer research 6, R149-156, doi: 10.1186/bcr767 (2004).
5. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752, doi: 10.1038/35021093 (2000).
6. Sørlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 100, 8418-8423, doi: 10.1073/pnas.0932692100 (2003).
7. de Ronde, J. J. et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast cancer research and treatment 119, 119-126, doi: 10.1007/s10549-009-0499-6 (2010).
8. Weigelt, B. et al. The molecular underpinning of lobular histological growth pattern: A genome-wide transcriptomic analysis of invasive lobular carcinomas and grade-and molecular subtype-matched invasive ductal carcinomas of no special type. The Journal of pathology 220, 45-57, doi: 10.1002/path.2629 (2010).
9. Bertucci, F. et al. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 27, 5359-5372, doi: 10.1038/onc.2008.158 (2008).
10. Ross, J. S. et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clinical cancer research 19, 2668-2676, doi: 10.1158/1078-0432.CCR-13-0295 (2013).
11. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 486 doi: 10.1038/nature10983 (2012).
12. TCGA. Comprehensive molecular portraits of human breast tumours. Nature, doi: 10.1038/nature11412 (2012).
13. Reed, A. E. M., Kutasovic, J. R., Lakhani, S. R. & Simpson, P. T. Invasive lobular carcinoma of the breast: Morphology, biomarkers and 'omics. Breast cancer research: 17, 336, doi: 10.1186/s13058-015-0519-x (2015).
14. Ciriello, G. et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 163, 506-519, doi: 10.1016/j. cell.2015.09.033 (2015).
15. Isserlin, R., Merico, D., Voisin, V. & Bader, G. D. Enrichment Map-a Cytoscape app to visualize and explore OMICs pathway enrichment results. F1000Research 3, doi: 10.12688/f1000research.4536.1 (2014).
16. Zwart, W. et al. Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer. The EMBO journal 30, 4764-4776, doi: 10.1038/emboj.2011.368 (2011).
17. Eeckhoute, J. et al. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer research 67, 6477-6483, doi: 10.1158/0008-5472.CAN-07-0746 (2007).
18. Theodorou, V., Stark, R., Menon, S. & Carroll, J. S. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Research, 23(1), 12-22. http://doi.org/10.1101/gr.139469.112.
19. Droufakou, S. et al. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. International Journal of Cancer 92, 404-408, doi: 10.1002/ijc.1208 (2001).
20. Buttitta, F. et al. PIK3CA mutation and histological type in breast carcinoma: High frequency of mutations in lobular carcinoma. The Journal of pathology 208, 350-355, doi: 10.1002/path.1908 (2006).
21. van Dyk, E., Reinders, M. J. T. & Wessels, L. F. A. A scale-space method for detecting recurrent DNA copy number changes with analytical false discovery rate control. Nucleic acids research, doi: 10.1093/nar/gkt155 (2013).
22. Lehn, S. et al. Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response. BMC cancer 14, 119, doi: 10.1073/pnas.96.20.11217 (2014).
23. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575, doi: 10.1038/nature11005 (2012).
24. Shen, R., Olshen, A. B. & Ladanyi, M. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics (Oxford, England) 25, 2906-2912, doi: 10.1093/bioinformatics/btp543 (2009).
25. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102, 15545-15550, doi: 10.1073/pnas.0506580102 (2005).
26. Anastassiou, D. et al. Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo. BMC cancer 11, 529, doi: 10.1186/1471-2407-11-529 (2011).
27. Andreou, A. Z. & Klostermeier, D. eIF4B and eIF4G Jointly Stimulate eIF4A ATPase and Unwinding Activities by Modulation of the eIF4A Conformational Cycle. J Mol Biol 426, 51-61.
28. Modelska, A. et al. The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape. Cell Death & Disease 6, e1603-1612, doi: 10.1038/cddis.2014.542 (2015).
29. Choi, Y. A. et al. Estradiol enhances CIP2A expression by the activation of p70 S6 kinase. Endocrine Related Cancer 21, 189-202, doi: 10.1530/ERC-13-0453 (2014).
30. Ali, H. R. et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Annals of oncology: 25, 1536-1543, doi: 10.1093/annonc/mdu191 (2014).
31. André, F. et al. Molecular pathways: Involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clinical cancer research: 19, 28-33, doi: 10.1158/1078-0432.CCR-11-2701 (2013).
32. Sistigu, A. et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature medicine 20, 1301-1309, doi: 10.1038/nm.3708 (2014).
33. Issa-Nummer, Y., Loibl, S., von Minckwitz, G. & Denkert, C. Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy. Oncoimmunology 3, e27926, doi: 10.4161/onci.27926 (2014).
34. Loi, S. et al. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. Journal of Clinical Oncology 31, 860-867, doi: 10.1200/JCO.2011.41.0902 (2013).
35. Wang, K. et al. PennCNV: An integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome research 17, 1665-1674, doi: 10.1101/gr.6861907 (2007).
36. Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proceedings of the National Academy of Sciences of the United States of America 107, 16910-16915, doi: 10.1073/pnas.1009843107 (2010).
37. Ali, H. et al. Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome biology 15, 431, doi: 10.1093/jnci/dju049 (2014).
38. Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (Oxford, England) 19, 185-193 (2003).
39. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics (Oxford, England) 8, 118-127, doi: 10.1093/biostatistics/kxj037 (2007).
40. Barbosa-Morais, N. L. et al. A re-annotation pipeline for Illumina BeadArrays: Improving the interpretation of gene expression data. Nucleic acids research 38, e17, doi: 10.1093/nar/gkp942 (2010).
41. Rondeau, S. et al. ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels. British journal of cancer 112, 1059-1066, doi: 10.1038/bjc.2015.60 (2015).
42. Troncale, S. et al. NormaCurve: A SuperCurve-Based Method That Simultaneously Quantifies and Normalizes Reverse Phase Protein Array Data. PloS one 7, e38686, doi: 10.1371/journal.pone.0038686 (2012).
43. Hothorn, T. & Lausen, B. Bagging tree classifiers for laser scanning images: A data-and simulation-based strategy. Artificial intelligence in medicine 27, 65-79 (2003).
44. Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome research 13, 2498-2504, doi: 10.1101/gr.1239303 (2003).
45. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome biology 15, 550, doi: 10.1186/s13059-014-0550-8 (2014).